Evidence map›Paper›PMID 35061678›Full record

ArticlePloS one

Homologous recombination DNA repair gene RAD51, XRCC2 & XRCC3 polymorphisms and breast cancer risk in South Indian women.

Taruna Rajagopal, Arun Seshachalam, Krishna Kumar Rathnam, Srikanth Talluri, Sivaramakrishnan Venkatabalasubramanian, Nageswara Rao Dunna

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Cancers · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Taruna RajagopalCancer Genomics Laboratory, Department of Biotechnology, School of Chemical and Biotechnology, SASTRA-Deemed University, Thanjavur, India.
Arun SeshachalamDepartment of Medical and Paediatric Oncology, Dr.G.V.N Cancer Institute, Singarathope, Trichy, India.ORCID https://orcid.org/0000-0002-8934-3696
Krishna Kumar RathnamDepartment of Hemato Oncology-Medical Oncology and Bone Marrow Transplantation, Meenakshi Mission Hospital & Research Centre, Madurai, India.
Srikanth TalluriDana Farber Cancer Institute, Boston, MA, United States of America.
Sivaramakrishnan VenkatabalasubramanianDepartment of Genetic Engineering, Faculty of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur Campus, Chennai, India.
Nageswara Rao DunnaCancer Genomics Laboratory, Department of Biotechnology, School of Chemical and Biotechnology, SASTRA-Deemed University, Thanjavur, India.ORCID https://orcid.org/0000-0001-5870-1035
SASTRA University · INCancer Institute (WIA) · INMeenakshi Mission Hospital and Research Centre · INSRM Institute of Science and Technology · INVA Boston Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHomologous recombination repair (HRR) accurately repairs the DNA double-strand breaks (DSBs) and is crucial for genome stability. Genetic polymorphisms in crucial HRR pathway genes might affect genome stability and promote tumorigenesis. Up to our knowledge, the present study is the first to investigate the impact of HRR gene polymorphisms on BC development in South Indian women. The present population-based case-control study investigated the association of polymorphisms in three key HRR genes (XRCC2-Arg188His, XRCC3-Thr241Met and RAD51-G135C) with BC risk. MATERIALS AND

methodsPolymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping the HRR variants in 491 BC cases and 493 healthy women.

resultsWe observed that the XRCC3 Met allele was significantly associated with BC risk [OR:1.27 (95% CI: 1.02-1.60); p = 0.035]. In addition, the homozygous mutant (C/C) genotype of RAD51 G135C variant conferred 2.19 fold elevated risk of BC [OR: 2.19 (95% CI: 1.06-4.54); p = 0.034]. Stratified analysis of HRR variants and BC clinicopathological features revealed that the XRCC3-Thr241Met and RAD51-G135C variants are associated with BC progression. Combined SNP analysis revealed that the individuals with RAD51-C/C, XRCC2-Arg/Arg, and XRCC3-Thr/Thr genotype combination have three-fold increased BC risk.

conclusionThe present study imparts additional evidence that genetic variants in crucial HRR pathway genes might play a pivotal role in modulating BC risk in South Indian women.

Indexed as

Breast NeoplasmsDNA-Binding ProteinsGenetic Predisposition to DiseasePolymorphism, Single NucleotideRad51 RecombinaseRecombinational DNA RepairAdultCase-Control StudiesFemaleGenotypeHumansIndiaMiddle AgedDNA-Binding ProteinsRAD51 protein, humanRad51 RecombinaseX-ray repair cross complementing protein 3XRCC2 protein, human

Identifiers

PMID35061678
PMCPMC8782413
OpenAlexW4206332542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.